Sector News

GW Pharmaceuticals hires investment bank following approaches

September 8, 2016
Life sciences

GW Pharmaceuticals Plc, a developer of marijuana-based epilepsy treatments, is working with an investment bank after other drugmakers approached it to express interest in an acquisition, people familiar with the matter said.

The move shows how the Cambridge, England-based company is emerging as a coveted target for larger pharmaceutical companies thanks to its key drug, Epidolex, which uses cannabis-based compounds to treat epilepsy.

GW has hired investment bank Morgan Stanley to help handle the overtures, the people said this week. The company is not currently interested in exploring a sale, and there is no certainty that any deal will occur, the people added.

The identity of the potential suitors could not be established. The sources asked not to be identified because the deliberations are confidential.

GW declined to comment. Morgan Stanley did not respond to a request for comment.

GW shares ended trading in London up 0.6 percent at 526.50 pence (70 U.S. cents), giving the company a market capitalization of 1.6 billion pounds ($2.1 billion). American depositary receipts of the company jumped as much as 22 percent in New York following the Reuters report.

GW’s move is the latest sign that dealmaking in the biotechnology sector is picking up. Last month, Pfizer Inc clinched a $14 billion acquisition of U.S. cancer drug company Medivation Inc.

Major players in the market for central nervous system treatments, including Allergan Plc and Biogen Inc , are searching for deals to build out their commercial presence and research and development pipelines.

Logical buyers for GW would include the companies that have partnered with it to distribute its marketed drug, Sativex, a nasal spray for multiple sclerosis that is also based on marijuana, one of the people said.

GW’s current partners include Novartis AG, Bayer AG and Almirall SA, among others.

Epidolex is in late-stage clinical trials and could receive approval from the U.S. Food and Drug Administration as soon as next year. It could eventually produce annual sales in excess of $800 million, according analysts at investment bank Cowen & Co.

The drug’s success is especially important to GW because of the tepid performance of Sativex, which has been marketed since 2010.

Sativex was never approved in the United States, and only produced $2 million in sales in the latest financial quarter.

GW Pharma is also exploring early-stage treatments for other illnesses, including diabetes and schizophrenia.

By Carl O’Donnell and Arno Schuetze

Source: Reuters

comments closed

Related News

February 4, 2023

MedTrace receives U.S. patent for diagnosing the human heart

Life sciences

The U.S. Patent and Trademark Office issued a patent to MedTrace for their method of diagnosing the human heart via 15O-water PET. The patented method is the foundation of the company’s software aQuant, currently under development. Hendrik “Hans” Harms, PhD and Senior Scientist at MedTrace, and Jens Soerensen, Professor and Clinical Advisor to MedTrace, are the originators of the method.

February 4, 2023

Roche taps insider Teresa Graham for top pharma job as setbacks prompt M&A questions

Life sciences

Teresa Graham, currently head of global product strategy for Roche pharma, will become the division’s new CEO next month, Roche said Thursday. Simultaneously, Roche is elevating Levi Garraway, chief medical officer, to the executive committee.

February 4, 2023

J&J’s pharma group quietly works through global overhaul, with layoffs expected to reach multiple countries

Life sciences

Fierce Pharma has obtained internal documents and video of a town hall meeting conducted this week describing what J&J called a “comprehensive review” of its portfolio. Moving forward, J&J plans to operate its vaccines and infectious diseases outfits as one group, the executives explained.

How can we help you?

We're easy to reach